155 related articles for article (PubMed ID: 1852896)
1. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
2. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
3. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.
Leonhardt A; Schweer H; Wolf D; Seyberth HW
Br J Clin Pharmacol; 1992 Mar; 33(3):323-5. PubMed ID: 1576056
[TBL] [Abstract][Full Text] [Related]
4. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.
Peskar BA; Cawello W; Rogatti W; Rudofsky G
J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.
Cawello W; Schweer H; Müller R; Bonn R; Seyberth HW
Eur J Clin Pharmacol; 1994; 46(3):275-7. PubMed ID: 8070511
[TBL] [Abstract][Full Text] [Related]
6. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.
Leonhardt A; Krauss M; Gieler U; Schweer H; Happle R; Seyberth HW
Br J Dermatol; 1997 Mar; 136(3):337-40. PubMed ID: 9115911
[TBL] [Abstract][Full Text] [Related]
7. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.
Schweer H; Meese CO; Watzer B; Seyberth HW
Biol Mass Spectrom; 1994 Mar; 23(3):165-70. PubMed ID: 8148408
[TBL] [Abstract][Full Text] [Related]
8. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
[TBL] [Abstract][Full Text] [Related]
9. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
[TBL] [Abstract][Full Text] [Related]
10. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766
[TBL] [Abstract][Full Text] [Related]
11. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
Pallapies D; Peskar BA
Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888
[TBL] [Abstract][Full Text] [Related]
12. Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma.
Schweer H; Cawello W; Seyberth HW
Prostaglandins Leukot Essent Fatty Acids; 1994 Dec; 51(6):401-5. PubMed ID: 7708804
[TBL] [Abstract][Full Text] [Related]
13. Identification of 6-keto-prostaglandin E1 obtained from isolated perfused kidney of the rabbit.
Pieroni JP; Dray F; Pace-Asciak CR; McGiff JC
J Pharmacol Exp Ther; 1988 Oct; 247(1):63-8. PubMed ID: 3139870
[TBL] [Abstract][Full Text] [Related]
14. Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease.
Creutzig A; Creutzig H; Alexander K
Eur J Clin Invest; 1986 Dec; 16(6):480-5. PubMed ID: 3104047
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the extent to exogenous prostaglandin I2 is converted to 6-keto-prostaglandin E1 in human subjects.
Jackson EK; Goodman RP; Fitzgerald GA; Oates JA; Branch RA
J Pharmacol Exp Ther; 1982 Apr; 221(1):183-7. PubMed ID: 7038095
[TBL] [Abstract][Full Text] [Related]
17. Identification of 6-oxo-prostaglandin E1 as a naturally occurring prostanoid generated by rat lung.
Berry CN; Griffiths RJ; Hoult JR; Moore PK; Taylor GW
Br J Pharmacol; 1986 Feb; 87(2):327-35. PubMed ID: 3955304
[TBL] [Abstract][Full Text] [Related]
18. Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.
Cawello W; Leonhardt A; Schweer H; Seyberth HW; Bonn R; Lomeli AL
Br J Clin Pharmacol; 1995 Sep; 40(3):273-6. PubMed ID: 8527291
[TBL] [Abstract][Full Text] [Related]
19. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics.
Bothwell W; Verburg M; Wynalda M; Daniels EG; Fitzpatrick FA
J Pharmacol Exp Ther; 1982 Feb; 220(2):229-35. PubMed ID: 6948952
[TBL] [Abstract][Full Text] [Related]
20. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
Creutzig A; Arnold A; Caspary L; Thum J; Alexander K
Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
